Ember Therapeutics Announces Publication in Circulation of Data Validating Utility of BMP-7 to Regulate Scar Formation in the Heart
July 17, 2017 12:22 ET
|
Ember Therapeutics
NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, fibrosis, and...
Ember Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
May 01, 2017 18:29 ET
|
Ember Therapeutics
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc., (OTCQB:EMBT) a publicly traded company is pleased to announced that it has retained Maxim Group LLC, a leading investment banking...
Ember Therapeutics Signs Endorsement Deal with 12 Time Olympic Medalist Ryan Lochte
October 03, 2016 16:55 ET
|
Ember Therapeutics
NEW YORK, Oct. 03, 2016 (GLOBE NEWSWIRE) -- EMBER THERAPEUTICS (OTCQB:EMBT), today announced that Olympic Gold Medalist Ryan Lochte has signed an endorsement agreement with the...
Ember Therapeutics Acquires Dermasilk™ Brands
September 12, 2016 14:47 ET
|
Ember Therapeutics
NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney...
Knight and Ember Expand Distribution Partnership
July 06, 2016 08:00 ET
|
Ember Therapeutics
MONTREAL and NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, and Ember Therapeutics, Inc....
Ember Therapeutics to Present at Marcum MicroCap Conference
May 31, 2016 13:31 ET
|
Ember Therapeutics
NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and...
Ember Therapeutics Acquires Migralex™
March 21, 2016 09:33 ET
|
Ember Therapeutics
NEW YORK, March 21, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis,...
Ember Therapeutics Enhances Regenerative Medicine Pipeline With Acquisition of ICX-RHY/Vavelta™ from Intercytex
March 16, 2016 08:30 ET
|
Ember Therapeutics
NEW YORK, March 16, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis,...
Ember Therapeutics, Inc. Announces Ticker Symbol Change to EMBT
February 23, 2016 17:02 ET
|
Ember Therapeutics
NEW YORK, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney...
Ember Therapeutics Completes Reverse Merger and Begins Trading as a Public Company
February 03, 2016 14:33 ET
|
Ember Therapeutics
NEW YORK, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc., a New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and...